Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

66. Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population Full Text available with Trip Pro

Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function decline in individuals with renal tubular diseases. It is not known whether this association also exists in the general population. Therefore, we investigated whether high UCaE is associated with risk of developing chronic kidney disease (CKD) in community-dwelling subjects.Urine samples of 5491 subjects who were free

2016 Kidney international reports

67. Calcium dobesilate for the treatment of chronic venous insufficiency

Calcium dobesilate for the treatment of chronic venous insufficiency Calcium dobesilate for the treatment of chronic venous insufficiency Calcium dobesilate for the treatment of chronic venous insufficiency Brito V, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Brito V, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Calcium dobesilate for the treatment of chronic venous insufficiency. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 487. 2016 Authors' conclusions Evidence of moderate quality shows that calcium dobesilate does not have a significant clinical impact on the progress of edema and ulcer healing, when

2016 Health Technology Assessment (HTA) Database.

68. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults Full Text available with Trip Pro

Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults To provide a management approach for adults with calcium channel blocker poisoning.Following the Appraisal of Guidelines for Research & Evaluation II instrument, initial voting statements were constructed based on summaries outlining the evidence, risks, and benefits.We recommend 1) for asymptomatic patients, observation and consideration of decontamination following a potentially toxic calcium (...) channel blocker ingestion (1D); 2) as first-line therapies (prioritized based on desired effect), IV calcium (1D), high-dose insulin therapy (1D-2D), and norepinephrine and/or epinephrine (1D). We also suggest dobutamine or epinephrine in the presence of cardiogenic shock (2D) and atropine in the presence of symptomatic bradycardia or conduction disturbance (2D); 3) in patients refractory to the first-line treatments, we suggest incremental doses of high-dose insulin therapy if myocardial dysfunction

2016 EvidenceUpdates

69. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Full Text available with Trip Pro

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis (...) and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known.The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided by an independent evidence

2016 Annals of Internal Medicine

70. Mitochondrial ROS versus ER ROS: Which Comes First in Myocardial Calcium Dysregulation? Full Text available with Trip Pro

Mitochondrial ROS versus ER ROS: Which Comes First in Myocardial Calcium Dysregulation? 27777931 2018 11 13 2297-055X 3 2016 Frontiers in cardiovascular medicine Front Cardiovasc Med Mitochondrial ROS versus ER ROS: Which Comes First in Myocardial Calcium Dysregulation? 36 Chaube Ruchi R Thrombosis and Atherosclerosis Research Institute, McMaster University , Hamilton, ON , Canada. Werstuck Geoff H GH Thrombosis and Atherosclerosis Research Institute, McMaster University , Hamilton, ON , Canada (...) . eng Journal Article 2016 10 10 Switzerland Front Cardiovasc Med 101653388 2297-055X calcium dysregulation endoplasmic reticulum stress heart failure mitochondrial ROS unfolded protein response 2016 05 22 2016 09 27 2016 10 26 6 0 2016 10 26 6 1 2016 10 26 6 0 epublish 27777931 10.3389/fcvm.2016.00036 PMC5056180 Int J Inflam. 2011;2011:514623 21860805 J Mol Cell Cardiol. 2010 Jun;48(6):1105-10 19913545 J Biol Chem. 2013 Aug 9;288(32):22961-71 23798702 Circ Res. 2003 Sep 19;93(6):487-90 14500331

2016 Frontiers in cardiovascular medicine

71. Calcium supplementation and risk of dementia in women with cerebrovascular disease Full Text available with Trip Pro

Calcium supplementation and risk of dementia in women with cerebrovascular disease To determine whether calcium supplementation is associated with the development of dementia in women after a 5-year follow-up.This was a longitudinal population-based study. The sample was derived from the Prospective Population Study of Women and H70 Birth Cohort Study in Gothenburg, Sweden, and included 700 dementia-free women aged 70-92 years. At baseline in 2000-2001, and at follow-up in 2005-2006, the women (...) underwent comprehensive neuropsychiatric and somatic examinations. A CT scan was performed in 447 participants at baseline. Information on the use and dosage of calcium supplements was collected. Dementia was diagnosed according to DSM-III-R criteria.Women treated with calcium supplements (n = 98) were at a higher risk of developing dementia (odds ratio [OR] 2.10, 95% confidence interval [CI] 1.01-4.37, p = 0.046) and the subtype stroke-related dementia (vascular dementia and mixed dementia) (OR 4.40

2016 EvidenceUpdates

72. Effect of Vitamin D and calcium supplementation on ischaemic stroke outcome: a randomised controlled open-label trial (Abstract)

Effect of Vitamin D and calcium supplementation on ischaemic stroke outcome: a randomised controlled open-label trial Vitamin D deficiency is a common problem in stroke survivors. Observational studies have reported an association of low vitamin D levels with greater stroke severity, poststroke mortality and functional disability. Randomised clinical trials are lacking. We sought to assess the effect of calcium and vitamin D supplementation in ischaemic stroke survivors with vitamin D (...) deficiency/insufficiency on disability/mortality outcomes.In this randomised controlled open-label trial, 73 patients of acute ischaemic stroke were screened for serum 25 hydroxy Vitamin D (25(OH)D) levels. A total of 53 patients with baseline 25(OH)D <75 nmol/L were randomised into two arms. One received vitamin D and calcium supplementation along with usual care (n=25) and the other received usual care alone (n=28). Primary outcome was the proportion of patients achieving a good outcome [modified

2016 EvidenceUpdates Controlled trial quality: predicted high

73. Structural insights into mitochondrial calcium uniporter regulation by divalent cations Full Text available with Trip Pro

Structural insights into mitochondrial calcium uniporter regulation by divalent cations Calcium (Ca(2+)) flux into the matrix is tightly controlled by the mitochondrial Ca(2+) uniporter (MCU) due to vital roles in cell death and bioenergetics. However, the precise atomic mechanisms of MCU regulation remain unclear. Here, we solved the crystal structure of the N-terminal matrix domain of human MCU, revealing a β-grasp-like fold with a cluster of negatively charged residues that interacts

2016 Cell chemical biology

74. Alanine to Serine Variant at Position 986 of Calcium Sensing Receptor and Colorectal Cancer Risk Full Text available with Trip Pro

Alanine to Serine Variant at Position 986 of Calcium Sensing Receptor and Colorectal Cancer Risk With regard to the effect of calcium against colorectal cancer (CRC) and considering the key role of calcium sensing receptor (CaSR) in calcium homeostasis, this study investigated whether CaSR gene rs1801725 or A986S variant was associated with susceptibility to CRC risk.This study was conducted as a case-control study and 303 cases with CRC and 354 controls were enrolled. All 657 subjects were

2016 Iranian journal of cancer prevention

75. Calcium Pyrophosphate Deposition Disease. Full Text available with Trip Pro

Calcium Pyrophosphate Deposition Disease. 27355536 2016 07 07 2018 12 07 1533-4406 374 26 2016 Jun 30 The New England journal of medicine N. Engl. J. Med. Calcium Pyrophosphate Deposition Disease. 2575-84 10.1056/NEJMra1511117 Rosenthal Ann K AK From the Division of Rheumatology, Department of Medicine, Medical College of Wisconsin (A.K.R., L.M.R.), and the Department of Medicine, Zablocki Veterans Affairs Medical Center (A.K.R.) - both in Milwaukee. Ryan Lawrence M LM From the Division (...) of Rheumatology, Department of Medicine, Medical College of Wisconsin (A.K.R., L.M.R.), and the Department of Medicine, Zablocki Veterans Affairs Medical Center (A.K.R.) - both in Milwaukee. eng I01 CX001143 CX CSRD VA United States Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Anti-Inflammatory Agents 0 Anti-Inflammatory Agents, Non-Steroidal 0 Glucocorticoids X69NU20D19 Calcium Pyrophosphate YL5FZ2Y5U1 Methotrexate AIM IM Anti-Inflammatory Agents therapeutic use Anti-Inflammatory

2016 NEJM

76. Apatite precipitation on a novel fast-setting calcium silicate cement containing fluoride Full Text available with Trip Pro

Apatite precipitation on a novel fast-setting calcium silicate cement containing fluoride Aim: Calcium silicate cements are widely used in endodontics. Novel fast-setting calcium silicate cement with fluoride (Protooth) has been developed for potential applications in teeth crowns including cavity lining and cementation. Objective: To evaluate the surface apatite-forming ability of Protooth compositions as a function of fluoride content and immersion time in phosphate-buffered saline (PBS (...) /belite Raman peak height indicated the apatite thickness. Results: Spherical calcium phosphate precipitations with acicular crystallites were formed after 1-day immersion in PBS and Raman spectra disclosed the phosphate band at 965 cm-1, supporting the apatite formation over Protooth compositions. The apatite deposition continued and more voluminous precipitations were observed after 56 days over the surface of all cements. Raman bands suggested the formation of β-type carbonated apatite over

2016 Acta biomaterialia odontologica Scandinavica

77. NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices

NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices UTCAT3059, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices Clinical Question In healthy adult patients, do NovaMin dentifrices reduce symptoms of dentinal (...) -treatment data). A similar but longer trial might simulate real-world use of these products better. Applicability Dentinal hypersensitivity is a common condition, and many patients ask their dentist or hygienist for treatment recommendations. NovaMin and potassium nitrate are dentifrices that are applied in the same manner and provide a noninvasive treatment option for patients with dentinal hypersensitivity. The cost of NovaMin (calcium sodium phosphosilcate) dentifrices is slightly greater than

2016 UTHSCSA Dental School CAT Library

78. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial Full Text available with Trip Pro

Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial To compare the effectiveness and safety of a cardiac computed tomography (CT) algorithm with functional testing in patients with symptoms suggestive of coronary artery disease (CAD).Between April 2011 and July 2013, 350 patients with stable angina, referred to the outpatient clinic of four Dutch hospitals, were (...) prospectively randomized between cardiac CT and functional testing (2 : 1 ratio). The tiered cardiac CT protocol included a calcium scan followed by CT angiography if the Agatston calcium score was between 1 and 400. Patients with test-specific contraindications were not excluded from study participation. By 1 year, fewer patients randomized to cardiac CT reported anginal complaints (P = 0.012). The cumulative radiation dose was slightly higher in the CT group (6.6 ± 8.7 vs. 6.1 ± 9.3 mSv; P < 0.0001

2016 EvidenceUpdates Controlled trial quality: uncertain

79. The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy Treatment

The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy Treatment UTCAT3013, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy (...) Treatment Clinical Question In patients undergoing chemotherapy, what is/are the effect(s) of casein phosphopeptide amorphous calcium phosphate fluoride (CPP-ACPF) products on oral and salivary status? Clinical Bottom Line For patients undergoing chemotherapy treatment, the application of casein phosphopeptide amorphous calcium phosphate fluoride (CPP-ACPF) paste twice daily can improve the resting & stimulated salivary rate and the buffering capacity. This finding is based on a randomized clinical

2016 UTHSCSA Dental School CAT Library

80. The effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (CPP-ACPF) on oral and salivary conditions of patients undergoing chemotherapy: A randomized controlled clinical trial. Full Text available with Trip Pro

The effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (CPP-ACPF) on oral and salivary conditions of patients undergoing chemotherapy: A randomized controlled clinical trial. Oral and saliva conditions of patients undergoing chemotherapy is often affected by the medication they receive. Up to now, no appropriate medication that possesses the positive effects of chemotherapy without presenting oral complications has been introduced.The aim of this study was to assess

2016 Electronic physician Controlled trial quality: uncertain